Filtered By:
Specialty: International Medicine & Public Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

The societal impact of inclisiran in England: Evidence from a population health approach
As first-in-class cholesterol-lowering small interfering ribonucleic acid (siRNA), inclisiran provides effective reductions in low-density lipoprotein cholesterol (LDL-C) to achieve better cardiovascular (CV) health. We estimate health and socioeconomic effects, of introducing inclisiran according to a population health agreement in England.
Source: Value in Health - May 12, 2023 Category: International Medicine & Public Health Authors: Dennis A. Ostwald, Maike Schmitt, Platon Peristeris, Tim Gerritzen, Adeline Durand Source Type: research

Ultrasound-triggered microbubble destruction enhances the radiosensitivity of glioblastoma by inhibiting PGRMC1-mediated autophagy in vitro and in vivo
ConclusionUTMD enhanced the radiosensitivity of glioblastoma partially by disrupting PGRMC1-mediated autophagy.
Source: Military Medical Research - February 14, 2022 Category: International Medicine & Public Health Source Type: research

Inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced blood –brain barrier injury through the Wnt/β-catenin signalling pathway
ConclusionThis study suggests that inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced BBB injury, and that the molecular mechanism involves the immunoproteasome-regulated activation of the Wnt/ β-catenin signalling pathway under ischemic conditions.
Source: Military Medical Research - December 3, 2021 Category: International Medicine & Public Health Source Type: research

Propofol postconditioning ameliorates hypoxia/reoxygenation induced H9c2 cell apoptosis and autophagy via upregulating forkhead transcription factors under hyperglycemia
ConclusionIt is concluded that propofol postconditioning attenuated H9c2 cardiac cells apoptosis and autophagy induced by H/R injury through upregulating FoxO1 and FoxO3a under hyperglycemia.
Source: Military Medical Research - November 10, 2021 Category: International Medicine & Public Health Source Type: research

RIG-I, a novel DAMPs sensor for myoglobin, activates NF- κB/caspase-3 signaling in CS-AKI model
ConclusionRIG-I is a novel damage-associated molecular patterns (DAMPs) sensor for myoglobin and participates in the NF- κB/caspase-3 signaling pathway in CS-AKI. In the development of CS-AKI, specific intervention in the RIG-I pathway might be a potential therapeutic strategy for CS-AKI.
Source: Military Medical Research - June 21, 2021 Category: International Medicine & Public Health Source Type: research

RIG-I, a novel DAMPs sensor for myoglobin activates NF- κB/caspase-3 signaling in CS-AKI model
ConclusionRIG-I is a novel damage-associated molecular patterns (DAMPs) sensor for myoglobin and participates in the NF- κB/caspase-3 signaling pathway in CS-AKI. In the development of CS-AKI, specific intervention in the RIG-I pathway might be a potential therapeutic strategy for CS-AKI.
Source: Military Medical Research - June 21, 2021 Category: International Medicine & Public Health Source Type: research

PCV24 A Threshold Analysis of the Cost-Effectiveness of Adjunctive Inclisiran Therapy for Ascvd Patients with LDL ≥70 MG/DL on Maximally Tolerated Statin Therapy
Inclisiran is a first-in-class, small-interfering ribonucleic acid (siRNA) that has been recently submitted to the Food and Drug Administration (FDA) for approval for the treatment of atherosclerotic cardiovascular disease (ASCVD) in patients with low-density lipoprotein (LDL) ≥70 mg/dL despite being on maximally tolerated statin therapy. We created a Markov model to estimate a range of value-based prices for inclisiran compared to currently available therapies: ezetimibe and the proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9s).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: K. Cai, B. Devine Source Type: research

Therapeutics that can shut down harmful genes need a reliable delivery system
(University of Texas at Austin) So far, only a handful of siRNA, or other RNA interference-based therapeutics that can shut down harmful genes to keep viruses from spreading have been approved. Chemical engineering researchers in the Cockrell School of Engineering have created several nanoparticles to help solve the problem of getting the siRNA into the body and guiding it to the target.
Source: EurekAlert! - Medicine and Health - May 17, 2021 Category: International Medicine & Public Health Source Type: news

Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Authors: Inukai D, Nishimura K, Okamoto H, Sano R, Ueda H, Ota A, Karnan S, Hosokawa Y, Yoshikawa K, Suzuki S, Ueda R, Murotani K, Bradford CR, Ogawa T Abstract Cisplatin is an important drug for the treatment of head and neck squamous cell carcinoma (HNSCC). Determining chemoresistant factors prior to treatment will lead to great benefits for clinicians and patients. Here, we evaluated chemoresistant factors by integrating proteomic and transcriptomic data using HNSCC cell lines to identify a more precise chemoresistant factor in HNSCC. We used four HNSCC cell lines: cisplatin-sensitive, acquired cisplatin resista...
Source: Nagoya Journal of Medical Science - November 4, 2020 Category: International Medicine & Public Health Tags: Nagoya J Med Sci Source Type: research

Green tea compound helps siRNA slip inside cells
(American Chemical Society) Drinking green tea has been linked to health benefits ranging from cardiovascular disease prevention to weight loss. Although many of these claims still need to be verified in the clinic, an antioxidant in green tea called epigallocatechin gallate (EGCG) appears to have beneficial effects in cells and animals. Now, researchers have found a surprising use for EGCG: sneaking therapeutic RNAs into cells. They report their results in ACS Central Science.
Source: EurekAlert! - Medicine and Health - September 19, 2018 Category: International Medicine & Public Health Source Type: news

Cancer treatment developed at Ben-Gurion U. changes cancer cells into normal ones
(American Associates, Ben-Gurion University of the Negev) " Using the siRNA treatment for several types of cancer in mouse models reprogramed cancer cell metabolism, reduced tumor growth and angiogenesis, reduced tumor invasiveness, and induced cancer stem cell disappearance and cell differentiation, " says BGU Prof. Shoshan-Barmatz.
Source: EurekAlert! - Medicine and Health - May 11, 2018 Category: International Medicine & Public Health Source Type: news

BGRF and SILS scientists analyze viability of shRNA therapy for Huntington's Disease
(Biogerontology Research Foundation) Researchers from the Biogerontology Research Foundation, Department of Molecular Neuroscience at the Swammerdam Institute for Life Sciences at the University of Amsterdam, and the Department of Neurobiology, Care Sciences and Society at the Karolinska Institute announce the publication of a paper in Translational Neurodegeneration, a BioMedCentral journal, titled RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA.
Source: EurekAlert! - Medicine and Health - December 1, 2017 Category: International Medicine & Public Health Source Type: news

Hepatitis C Treatment with First-Generation Protease Inhibitors in A Real-World Cohort: Risk-Benefit Profile and Costs of the Therapy
In Italy, since 2013, boceprevir and telaprevir, first-generation protease inhibitors, in combination with peginterferon and ribavirin have been approved for HCV (genotype-1) treatment.  The aim of this study is to evaluate the real life response rate using sustained viral response (SVR) and associated overall costs in a “difficult-to-treat” cohort.
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: I Cacciola, C Giardina, V Sirna, R Macr ì, A D'Ausilio, A Aiello, E Latorre, M Toumi, R Filomia, G Raimondo, V Arcoraci, AP Caputi Source Type: research

Neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries - Kwon EJ, Skalak M, Lo Bu R, Bhatia SN.
Traumatic brain injuries (TBIs) affect 2.5 million Americans per year, and survivors of TBI can develop long-term impairments in physical, cognitive, and psychosocial functions. Currently, there are no treatments available to stop the long-term effects of ...
Source: SafetyLit - August 19, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

PT167 RU360 Adsorption in Silica Nanovectors: Potential Use Against Mitochondrial Dysfunction in Heart Failure
Heart failure is the clinical syndrome causing the highest number of adult deaths in industrialized countries, with an annual death rate of 20-40% of the diagnosed cases. There are numerous candidates for heart failure therapy involving regulation of mitochondrial calcium ([Ca2+]m) through the Mitochondrial Calcium Uniporter (MCU), such as the use of Ru360 for inhibition or gene silencing using siRNA. However, their bioavailability is low. Recently, the use of nanovectors as means for drug delivery have been explored given that those could increase the drug bioavailability along with time-programmed drug release.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: O. Lozano, Y. Oropeza, N. Ornelas, F. Contreras, E. Guerrero-Beltr án, E. Vázquez-Garza, S.E. Cárdenas, G. Torre-Amione, G. García-Rivas Tags: Poster Abstract Source Type: research